T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study (STARTREK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00986518|
Recruitment Status : Completed
First Posted : September 30, 2009
Last Update Posted : November 25, 2013
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Biological: Adaptive autologous cell immunotherapy||Phase 1 Phase 2|
The primary goal of the proposed clinical trial is to eliminate cancer tumor using an autologous cell therapy aiming at mounting an efficient immune anti-tumor response by selectively depleting regulatory T-cell during a controlled amount of time. This strategy will be tested in patients with hepatic metastases from colorectal who are not eligible for surgery.
This is an open-label single cohort phase I-II therapeutic trial. Patients with hepatic metastases from primary colorectal cancer, not eligible to surgery and relapsing from conventional chemotherapy and/or targeted therapy, will be included.
Following patient inclusion:
- A lymphapheresis will be performed at D-15 which will be subjected to cell sorting /purification of regulatory T cells on the one hand and T lymphocytes depleted from regulatory T cells (effectors T-cells) on the other, and subsequently frozen and stored (The procedures for ex vivo regulatory T cell depletion has been validated in a previous study - AFSSAPS- TC 192) ;
- A lymphoid-ablative chemotherapy (cyclophosphamide + fludarabine) will be perform from D1 to D5,
- Autologous effector T-cells administration will be performed at D7. Efficacy will be assessed through tumor size change. Change in tumor size will be assessed with CTscans (RECIST criteria), MRIs (functional criteria following injection: DCEMRI and diffusion MRI to assess change in cellularity and tumor necrosis and morphological criteria RECIST), and sonography with contrast injection (to assess vascular microcirculation). Assessments will be done prior to lymphoid-ablation and then monthly for 9 months. Safety will be systematically assessed daily during in-patient period using the World Health Organisation - Common Toxicity Criteria (WHO-CTC).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Controlled and Selective Depletion of Regulatory T-cell for Cancer Treatment, Efficacy and Safety Study|
|Study Start Date :||October 2012|
|Primary Completion Date :||February 2013|
|Study Completion Date :||February 2013|
|Experimental: adaptive cell immunotherapy||
Biological: Adaptive autologous cell immunotherapy
each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
- Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria) [ Time Frame: from Month 1 to Month 9 ]
- MRI : Assessment of tumor necrosis, cellularity and morphological criteria RECIST 1.1 (functional criteria following injection : DCEMRI and diffusion MRI) [ Time Frame: Month 1 to Month 9 ]
- Sonography : assessment of vascular micro-circulation with contrast injection, [ Time Frame: Month 1 to Month 9 ]
- Immune cell reconstitution will be assessed through measuring rate of regulatory T-cell reconstitution, [ Time Frame: day 7 to 28 ]
- Clinical Exam (WHO-CTC), Vital Signs, Adverse events [ Time Frame: day 1 to 28 ]
- Laboratory test: hepatic function, immune function, haematology [ Time Frame: day 1 to 28 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986518
|Service hépato-gastro-enterologie, Pitié-Salpêtrière Hospital|
|Paris, France, 75013|
|Principal Investigator:||David Klatzmann, MD, PhD||Pitié-Salpêtrière Hospital|